About 70% of estrogen receptor (ER) positive breast cancers have significantly reduced the risk of invasive breast cancer by various endocrine therapies. Despite the relative safety and significant anti-neoplastic and chemopreventive activities of tamoxifen and aromatase inhibitors, many initially responsive breast tumors develop resistance and ultimately recur.
My current research is to investigate the secretome leading to the endocrine resistance in crosstalk between endocrine resistant breast cancer and tumor microenvironment.
The long-term mission of my laboratory is to understand the steps of the endocrine resistant process in order to develop therapeutic approaches to prevent and treat endocrine resistant breast cancer effectively. The ultimate goal of my research is to bring therapies into the clinic that will improve the survival of metastatic breast cancer patients
